Synthesis of JNJ-26076713

W. A. Kinneyet al.

doi:10.1055/s-2008-1078181

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synfacts 2008(10): 1012-1012
DOI: 10.1055/s-2008-1078181

Synthesis of Natural Products and Potential Drugs

Synthesis of JNJ-26076713

Contributor(s): Philip Kocienski, Stewart Eccles
W. A. Kinney et al.*
Johnson & Johnson Pharmaceutical Research and Development, Spring House, USA

Further Information

Publication History

Publication Date:
22 September 2008 (online)

Permissions and Reprints

Significance

JNJ-26076713 is an α_Vβ₃/α_Vβ₅ integrin antagonist with efficacy in eye disease models of angiogenesis and vascular permeability. JNJ-26076713 shows good potency, oral bioavailability, selectivity and half-life.